ARTICLES BY LOUIS

• Janssen Goes From Good To Excellent Supply Chain Partners

  4/20/2018

  Great questions elicit enlightening answers. Especially when the first come from a wise moderator (Brendan Crowley, President, Brendan Crowley Advisors LLC), and the second a seasoned industry veteran (Remo Colarusso, Vice President, Janssen Supply Chain, Johnson & Johnson). Here’s what they had to say about drug development and manufacturing partners.

• Pfizer's Drivers for Manufacturing: New Tech And Regulators

  4/12/2018

  Regarding drug development and manufacturing – including outsourcing – Bob Betzig of Pfizer says technology has led and continues to drive change. And by the way, so do the global regulators of biopharma. 

• 6 Challenges For BioPharma Packaging

  4/2/2018

  Whether it’s innovative product-development; the need to operate globally; dealing with aging and unhealthy populations; stopping counterfeiting and theft; or facing un-harmonized serialization … biopharma packaging has its challenges.    

• A View Of Biopharma From Pfizer's Building 41

  3/20/2018

  This is the story of a man and a building, and their tracing of decades — and hints of the future — at Pfizer, and indeed the entire biopharma industry.

• 3 Questions To Guide You At Biopharma Conferences

  3/14/2018

  It’s conference season: Time for you — biopharma CEO and new employee alike — to learn and lead among others in the industry. Unfortunately, you may come up short. Here are 3 questions of existential importance to ensure that doesn’t happen at your next conferences. 

• Large Or Small Molecule: Drug Sponsors Share API Outsourcing Philosophy

  3/2/2018

  Industry Standard Research (ISR) has released two reports – one on the API outsourcing preferences and practices of small-molecule drug sponsors, and the other on those of large-molecule sponsors. I also undertook some additional analysis by comparing the reports. My driving question: Are there strategic and tactical differences for the two programs when outsourcing to CMOs? 

• The World's First Biopharma Built On Blockchain

  2/22/2018

  The world’s first biopharma built on blockchain technology has arrived. “We’ve created a new generation of pharmaceutical company, focused on dispersed product development through the use of today’s technology,” says Dr. Matthew Lee, Caywon Pharmaceutical Group’s VP of Innovations.

• From CMO To CMO: A Biopharma With All The Right Moves

  2/15/2018

  There’s a quotidian calculation to outsourcing at Allena Pharmaceuticals that's well worth studying.

  “As a small biotech, we could get kicked to the curb because somebody else has more dollars, and can occupy longer those assets at a CMO that we need. Because of this, we’ve evolved a concept of portability for our manufacturing process that may be anathema to a lot of companies …"

• Biopharma's Technology Scouts: Time To Look At CDMOs, Too?

  2/2/2018

  We’ve heard stories where service providers bring ideas for innovations to biopharma clients, but get rebuked because of the immediate focus on the bottom line for services. Perhaps sponsors should make a new comparison: Where is innovative, biopharma-applicable new-tech, perhaps already focused on elements of a drug owner’s pipeline, actually cheaper to come by? 

• Hospitals To Serve Up IVs, And Now APIs?

  1/24/2018

  Outsourced Pharma readers must be scratching your heads over the mass-media reported news splash that Intermountain Healthcare is leading four U.S.-based “health care systems” in a consortium to form a generic drug company. In other words, hospitals are getting into APIs. And this, we are told, will save the world from shortages, while reducing pricing for generic drugs. Let’s just say some questions remain, such as: “How’s that all going to work?”